14062-21-6

Usage

InChI:InChI=1/C13H18O2/c1-4-15-13(14)9-11-5-7-12(8-6-11)10(2)3/h5-8,10H,4,9H2,1-3H3

Upstream product

• 4395-87-3 (4-isopropylphenyl)acetonitrile 
• 64-17-5 ethanol 
• 54264-18-5 1-Isopropyl-4-((Z)-2-methanesulfinyl-2-methylsulfanyl-vinyl)-benzene 
• 4476-28-2 (4-isopropylphenyl)acetic acid 
• 98-82-8 Isopropylbenzene 
• 75-36-5 acetyl chloride 
• 99-89-8 4-Isopropylphenol 
• 105-36-2 ethyl bromoacetate 
• 122-03-2 (4-isopropylbenzaldehyde) 
• 2051-18-5 4-isopropylbenzyl chloride 
• 99-87-6 4-methylisopropylbenzene 
• 50-00-0 formaldehyd 
• 143-33-9 sodium cyanide 

Downstream Products

• 97621-10-8 2-(4-isopropylphenyl)malonic acid diethyl ester 
• 75239-39-3 ethyl ester of p-isopropyl-2-phenyl-3-hydroxypropane acid 
• 1643-16-9 2-(4-isopropylphenoxy)acetic acid 
• 35341-50-5 7-isopropyl-3,4-dihydro-2H-naphthalen-1-one-(2,4-dinitro-phenylhydrazone) 
• 859196-94-4 (4-isopropyl-phenethyl)-methyl-malonic acid diethyl ester 
• 35338-69-3 (4-isopropyl-phenethyl)-malonic acid diethyl ester 
• 35338-72-8 7-isopropyl-3,4-dihydro-2H-naphthalen-1-one 
• 35338-68-2 p-isopropylphenethyl bromide 
• 83055-22-5 3-{2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-acetoxy}-2-(4-isopropyl-phenyl)-propionic acid 
• 83055-25-8 3-{2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-acetoxy}-2-(4-isopropyl-phenyl)-propionic acid; compound with cyclohexylamine 
• 83055-27-0 p-isopropyl-2-phenyl-3-hydroxypropane acid 
• 773851-52-8 4-(4-isopropyl-phenyl)-2H-isoxazol-5-one 
• 926008-75-5 {4-[6-chloro-5-(4-isopropylphenyl)pyrimidin-4-ylethynyl]phenyl}dimethylamine 
• 146533-34-8 4,6-dichloro-5-(4-isopropyl-phenyl)-pyrimidine 

Relevant academic research and scientific papers

4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT-702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-ylpyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed.

PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.